Showing 20 of 55 recruiting trials for “classic-hodgkin-lymphoma-mixed-cellularity-type”
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
👨⚕️ Narendranath Epperla, MD, MS, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Oct 2025View details ↗
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
👨⚕️ Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
👨⚕️ Evgeny E Zvonkov, MD, PhD, National Medical Research Center for Hematology📍 1 site📅 Started Jul 2025View details ↗
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
👨⚕️ Andrey Kaprin, FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation📍 1 site📅 Started Apr 2025View details ↗
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
👨⚕️ Alessandra Tucci, Dr.ssa, UO Ematologia, ASST Spedali Civili di Brescia, Piazzale Spedali Civili, 1, 25123 Brescia, Italia📍 20 sites📅 Started Apr 2025View details ↗
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
👨⚕️ Ryan Lynch, MD, Fred Hutch/University of Washington Cancer Consortium📍 5 sites📅 Started Mar 2025View details ↗
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
👨⚕️ Aibin Liang MD,Ph.D., Shanghai Tongji Hospital, Tongji University School of Medicine📍 1 site📅 Started Dec 2024View details ↗
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Dec 2024View details ↗
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
👨⚕️ Natalia Mikhailova, MD, PhD, St. Petersburg State Pavlov Medical University📍 1 site📅 Started Oct 2024View details ↗
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
👨⚕️ Natalia Mikhailova, MD, St. Petersburg State Pavlov Medical University📍 3 sites📅 Started Sep 2024View details ↗
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →